In our opinion, patients with active hepatitis D with HDV RNA positive and elevated ALT or hepatic fibrosis ≥2, treatment with PegIFN-α-2a or PegIFN-α-2b 180 μg weekly should be initiated if there is no contraindication. The gene discussed is GPT; the disease is hepatitis D virus infection.